Antibody-drug conjugates for the treatment of breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on antibody-drug conjugates (ADCs) for the treatment of breast cancer, focusing on HER2-postive. TROP-2 expression appears to correspond to the activity of sacituzumab govitecan, whereby those with higher expression demonstrate superior activity. The Phase III ASCENT trial (NCT02574455) showed a significant improvement in progression-free survival (PFS), as well as overall-survival (OS), in patients with metastatic triple-negative breast cancer (mTNBC) with the TROP-2-directed ADC. Further data on TROP-2-directed ADCs will be provided by the TROPION-Breast01 Phase III Trial investigating datopotamab deruxtecan in patients with HR-positive, HER2-negative inoperable or metastatic breast cancer previously treated with chemotherapy. Currently, there is uncertainty surrounding whether HER3 is relevant for ADCs. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.